J. Schütte

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA · 2012 · 969 citations

Medicine, Oncology, Surgery +12

jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun

J. Schütte, Jean Viallet, Marion M. Nau et al. · Cell · 1989 · 487 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +6

Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene.

J. Schütte, J D Minna, M. J. Birrer · Proceedings of the National Academy of Sciences · 1989 · 251 citations · Full text

Medicine, Genetics, Molecular Biology +15

Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination.

M. Krismann, B Todt, J.‐M. Schröder et al. · Journal of Clinical Oncology · 1995 · 196 citations

Medicine, Cell Biology, Oncology +13

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA Oncology · 2020 · 180 citations · Full text

Medicine, Oncology, Surgery +15